Clinical trial · Interventional
Neo-TACE-HAIC for PVTT-HCC
Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: a Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for treatments. Although BCLC (Barcelona clinical liver cancer) system recommend to palliative targeted treatment, the East Asian countries recommend to resection or transartery chemoembolization (TACE). Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate. Whether TACE-HAIC would improve survival for patients with PVTT is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Portal Vein Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neo-TACE-HAIC+Surgery | Procedure | — | UNRESOLVED |
| Surgery alone | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- neo-TACE-HAIC with surgery
- description
- neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
- interventionNames
- Procedure: neo-TACE-HAIC+Surgery
- type
- ACTIVE_COMPARATOR
- label
- surgery alone
- description
- surgery alone for HCC patients with PVTT
- interventionNames
- Procedure: Surgery alone
Primary outcomes (1)
- measure
- Progression-free survival, PFS
- timeFrame
- 36 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-75 years; * Patients with resectable primary hepatocellular carcinoma and portal vein tumor thrombus, which was not located in main portal vein; * Child-Pugh A or B (7 score) liver function; * With more than 3 months expected survival; * The volume of residual liver more than 30% Exclusion Criteria: * Patients with primary hepatocellular carcinoma and major portal vein tumor thrombus * With extrahepatic metastasis or unresectable HCC * Pregnant woman or sucking period; * With other malignant cancer; * Received chemotherapy, target therapy or immunosuppressive drugs therapy before this study.
References
Publications (0)
Data not yet available